This article is more than 5 years old. Information may no longer be current.
Bioventus announces expansion of surgical orthobiologics portfolio offering with Premier
Click Here to Manage Email Alerts
Bioventus announced its full surgical orthobiologics portfolio is available through Premier Inc., effective June 1, according to a company press release.
“The Bioventus surgical portfolio is designed to meet the needs of surgeons and their patients, across a broad range of clinical situations, procedures and costs,” Henry Tung, MD, senior vice president of Bioventus and president of Bioventus Surgical, said in the release. “We expect the Premier alliance of hospitals and health care providers to benefit greatly from our clinically supported and cost-effective orthobiologic solutions.”
Under the agreement, products included in the portfolio are Signafuse, a bioactive bone graft substitute; Exponent demineralized bone matrix; Purebone demineralized cancellous bone and cancellous chips; Interface bioactive bone graft; Osteomatrix, a biphasic mineral/collagen bone graft; Osteoplus biphasic mineral bone graft; Cellxtract, an autologous cell and marrow extraction device; and Extractor, an autologous cell and marrow extraction device.
Reference: